Volkan Sumer, DO
Family Medicine · Pekin, ILNPI 1730185125
Payments from drug & device makers
Across 144 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$614
- AbbVie$339
- Astellas Pharma US Inc$314
- Novo Nordisk$243
- Novartis$199
- GSK$193
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,07492%
- Education$2808%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $614 |
| AbbVie(2 entities) | 12 | $339 |
| Astellas Pharma US Inc | 6 | $314 |
| Novo Nordisk | 7 | $243 |
| Novartis | 9 | $199 |
| GSK | 9 | $193 |
| Pfizer | 19 | $184 |
| Abbott | 10 | $179 |
| Boehringer Ingelheim | 7 | $161 |
| Amgen | 7 | $140 |
| Dexcom, Inc. | 2 | $109 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Johnson & Johnson | 2 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Pacira Therapeutics, Inc. | 3 | $45 |
| Lilly USA, LLC | 3 | $40 |
| Orthogenrx Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Exact Sciences | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Avanos Medical | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,354 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $163,083 |
| JardianceEmpagliflozin | 48 | $46,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $45,242 |
| JanuviaSitagliptin Phosphate | 44 | $41,773 |
| XareltoRivaroxaban | 45 | $37,005 |
| OzempicSemaglutide | 24 | $34,746 |
| MounjaroTirzepatide | 24 | $23,919 |
| FarxigaDapagliflozin Propanediol | 12 | $14,974 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,428 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,235 |
| Spiriva HandihalerTiotropium Bromide | 13 | $10,538 |
| MyrbetriqMirabegron | 14 | $8,928 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $8,141 |
| SynthroidLevothyroxine Sodium | 68 | $6,592 |
| LinzessLinaclotide | 11 | $5,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $163,083206 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $193 | $67,90591 claims |
| Boehringer IngelheimJardiance | $161 | $46,28648 claims |
| Johnson & JohnsonXarelto | $55 | $37,00545 claims |
| Novo NordiskOzempic | $243 | $34,74624 claims |
| Lilly USA, LLCMounjaro | $40 | $23,91924 claims |
| AstraZenecaFarxiga, Symbicort | $614 | $19,97630 claims |
| AbbVieSynthroid, Linzess | $339 | $12,50779 claims |
| Astellas Pharma US IncMyrbetriq | $314 | $8,92814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Pekin
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.